On June 4, SynAct Pharma hosted a Capital Markets Day to present its refined development strategy, including the launch of development initiatives in polymyalgia rheumatica. On the same day, the company announced a directed share issue of approximately SEK 37 million, along with a SEK 30 million credit facility – together securing a financial runway through the end of 2026.

Read the article at biostock.se

https://biostock.se/2025/06/synact-pharma-refines-development-strategy-and-extends-financial-runway-through-2026/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

SynAct Pharma

Senast

20,65

1 dag %

−3,05%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån